AAV mutants with brain targeting properties

By introducing amino acid changes at specific positions of the AAV2 capsid protein, brain-oriented AAV particles were prepared, solving the problem of low efficiency in gene delivery to brain cells and achieving highly efficient gene transduction.

CN113748122BActive Publication Date: 2024-11-22TAKARA BIO INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202080030827.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-24
Filing Date
2020-04-23
Publication Date
2024-11-22
Estimated Expiration
2040-04-23

AI Technical Summary

Technical Problem

Existing technologies are insufficient for effectively introducing genes into brain cells, and the lack of brain-oriented AAV capsid protein mutants results in low gene transduction efficiency.

Method used

By introducing amino acid substitutions, deletions, insertions, or additions at specific positions in the AAV2 capsid protein, mutants of the AAV capsid protein containing specific amino acid sequences are prepared, forming brain-oriented AAV particles.

Benefits of technology

AAV particles were used to efficiently transduce genes into brain cells, and the strongly expressed genes significantly accumulated in brain tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113748122B_ABST
    Figure CN113748122B_ABST
Patent Text Reader

Abstract

The present invention provides a nucleic acid encoding an adeno-associated virus (AAV) capsid protein mutant, wherein the mutant contains a peptide comprising an amino acid sequence selected from SEQ ID No.15-62 or a peptide comprising an amino acid sequence produced by replacing, deleting, inserting and / or adding one or more amino acid residues in an amino acid sequence selected from SEQ ID No.15-62; a DNA comprising the nucleic acid; a cell having the DNA; and a method for producing the cell.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to nucleic acids encoding adeno-associated virus (AAV) capsid protein mutants having brain tropism, AAV particles containing the capsid protein variants, and methods for producing gene-transduced cells by using the particles. Background Art

[0002] AAV is a virus with a 4.7 kb linear single-stranded DNA genome (including open reading frames of two genes, rep and cap). The rep gene encodes four proteins necessary for genome replication (Rep78, Rep68, Rep52 and Rep40). The cap gene expresses three capsid proteins (VP1, VP2, VP3) that are assembled to form the viral capsid, as well as assembly-activating protein (AAP). The replication of AAV in nature depends on the presence of helper viruses (such as adenovirus or herpes virus). In the absence of helper viruses, the genome of AAV is maintained in an episome or integrated into the chromosome of the host so that AAV exists in a latent state. More than one hundred serotypes and evolutionary branches of AAV have been identified (Non-patent Document 1). In particular, the development of gene delivery vectors based on AAV2 has been promoted.

[0003] In 1989, the AAV2-based gene delivery vector system was first developed. AAV-based vectors have been found to have many advantages. Since wild-type AAV is non-pathogenic and has no etiological relationship with any known disease, AAV-based vectors are considered to be very safe. In addition, AAV has a high gene transduction efficiency.

[0004] The administration of AAV particles realizes long-term and stable gene transduction into various target organs and target cells. So far, it has been reported that gene transduction with high efficiency enters skeletal muscle, liver (hepatocytes), heart (cardiomyocytes), nerve cells, pancreatic cells and islet cells. In addition, AAV has been used in human clinical trials. On the other hand, attempts to change the cell tropism of AAV by changing the AAV capsid protein have been made, as well as attempts to avoid removing AAV particles by neutralizing antibodies. For example, AAV capsids with tropism to specific organs and cells (such as glial cells, airway epithelial cells, coronary artery endothelial cells and lungs) have been produced, as well as AAV capsids with tropism to tumor cells (such as glioblastoma cells, melanoma cells, lung cancer cells and breast cancer cells) (non-patent literature 2).

[0005] Citation List

[0006] Non-patent literature

[0007] Non-patent document 1: Gao et al., J. Virology, Vol. 78, pp. 6381-6388, 2004

[0008] Non-patent document 2: Adachi K. et al., Gene Ther. Regul., Vol. 5, pp. 31-55, 2010 SUMMARY OF THE INVENTION

[0010] Problems to be solved by the present invention

[0011] The objects of the present invention include providing AAV capsid protein mutants with brain tropism and providing methods for efficiently introducing genes into the brain.

[0012] Solution to this problem

[0013] The present inventors have made intensive efforts to solve the above problems, and as a result, have produced the desired AAV particles, wherein the AAV particles contain an AAV capsid protein containing an amino acid sequence selected from SEQ ID NOs: 15 to 62. Thus, the present invention has been completed.

[0014] The present invention generally relates to:

[0015] [1] A nucleic acid encoding an adeno-associated virus (AAV) capsid protein mutant, the mutant comprising a peptide comprising an amino acid sequence selected from SEQ ID NOs: 15-62 or a peptide comprising an amino acid sequence different from an amino acid sequence selected from SEQ ID NOs: 15-62 due to substitution, deletion, insertion and / or addition of one or more amino acids;

[0016] [2] The nucleic acid according to [1], wherein the AAV capsid protein is derived from AAV2;

[0017] [3] The nucleic acid according to [2], wherein the peptide is placed between amino acid number 588 and amino acid number 589 in VP1 of AAV2;

[0018] [4] A recombinant DNA comprising the nucleic acid according to any one of [1] to [3];

[0019] [5] A cell comprising the nucleic acid according to any one of [1] to [3] or the recombinant DNA according to [4];

[0020] [6] An AAV particle comprising an AAV capsid protein mutant, wherein the mutant comprises a peptide comprising an amino acid sequence selected from SEQ ID NOs: 15-62 or a peptide comprising an amino acid sequence different from an amino acid sequence selected from SEQ ID NOs: 15-62 due to substitution, deletion, insertion and / or addition of one or more amino acids;

[0021] [7] AAV particles according to [6], wherein the AAV capsid protein is derived from AAV2;

[0022] [8] An AAV particle according to [7], wherein the peptide is placed between amino acid number 588 and amino acid number 589 in VP1 of AAV2;

[0023] [9] A method for producing gene-transduced cells, the method comprising the step of contacting an AAV particle containing an AAV capsid protein mutant with a cell, wherein the mutant comprises a peptide containing an amino acid sequence selected from SEQ ID NOs: 15-62 or a peptide containing an amino acid sequence different from the amino acid sequence selected from SEQ ID NOs: 15-62 due to substitution, deletion, insertion and / or addition of one or more amino acids;

[0024]

[10] The method according to [9], wherein the AAV capsid protein is derived from AAV2; and

[0025]

[11] The method of

[10] , wherein the peptide is placed between amino acid number 588 and amino acid number 589 in VP1 of AAV2.

[0026] Effects of the Invention

[0027] According to the present invention, a gene transduction system useful for gene transduction into the brain is provided. The AAV particles of the present invention have high cell tropism for the brain, and genes transduced by the AAV particles can be strongly expressed. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] [ Figure 1 ] Figure 1 Methods for generating nucleic acid constructs for enabling capsid proteins to contain random peptides are demonstrated.

[0030] [ Figure 2 ] Figure 2 The results of evaluating the tropism of the AAV capsid protein mutants of the present invention are shown.

[0031] Modes for Carrying Out the Invention

[0032] As used herein, "adeno-associated virus" refers to a virus belonging to the genus Dependovirus ( Dependovirus ) of the Parvoviridae family ( Parvoviridae) and can infect primates and other mammals including humans. Hereinafter, adeno-associated virus is referred to as AAV. AAV has a non-enveloped icosahedral shell (capsid) and a linear single-stranded DNA in the shell. As used herein, AAV includes wild-type viruses and derivatives thereof, and unless otherwise specifically stated, includes all serotypes and clades of AAV.

[0033] As used herein, "vector" means a molecule or associated molecule used to mediate the delivery of a polynucleotide to a cell, and which contains or is associated with a polynucleotide. Unless otherwise specifically stated, examples of vectors include vector DNA (such as plasmid vectors and phage vectors), viral vector particles, liposomes, and other carriers for gene delivery.

[0034] As used herein, "capsid protein" means a protein encoded by the cap gene present in the AAV genome and constituting the AAV capsid. The wild-type AAV genome encodes three capsid proteins, VP1, VP2 and VP3. As used herein, the capsid protein comprises VP1, VP2 and VP3.

[0035] As used herein, the term "several" in the context of amino acid substitutions, deletions, insertions and / or additions means, for example, 2, 3, 4, 5, 6, 7, 8 or 9 amino acids, depending on the length of the reference amino acid sequence.

[0036] (1) Nucleic acid encoding AAV capsid protein mutant

[0037] The nucleic acid of the present invention encodes a mutant of an AAV capsid protein, which comprises a peptide comprising an amino acid sequence selected from SEQ ID NO: 15-62 or a peptide comprising an amino acid sequence different from an amino acid sequence selected from SEQ ID NO: 15-62 due to substitution, deletion, insertion and / or addition of one or several amino acids. Preferably, the nucleic acid of the present invention encodes an AAV capsid protein mutant, which comprises a peptide comprising an amino acid sequence selected from SEQ ID NO: 15 to SEQ ID NO: 62. More preferably, the nucleic acid of the present invention encodes an AAV capsid protein mutant, which comprises a peptide comprising an amino acid sequence selected from SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 or a peptide comprising an amino acid sequence different from an amino acid sequence selected from SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 due to substitution, deletion, insertion and / or addition of one or several amino acids. A peptide containing an amino acid sequence that is different from the amino acid sequence shown in the above SEQ ID NO due to substitution, deletion, insertion and / or addition of one or more amino acids, when contained in an AAV capsid protein, retains the cell tropism of the AAV capsid protein mutant containing the peptide containing the amino acid sequence shown in the above SEQ ID NO. In other words, the number of amino acids substituted, deleted, inserted and / or added in the amino acid sequence shown in the above SEQ ID NO is not limited, as long as the peptide containing the amino acid sequence shown in the above SEQ ID NO is retained to confer the cell tropism of the AAV capsid protein mutant containing the peptide. For example, 1 to 5, preferably 1 to 4, more preferably 1, 2 or 3 amino acids may be substituted, deleted and / or inserted. For example, 1 to 9, preferably 1 to 8, more preferably 1 to 7, even more preferably 1 to 6, even more preferably 1 to 5, even more preferably 1, 2, 3 or 4 amino acids may be added.

[0038] For example, the peptide to be included in the AAV capsid protein mutant may be a peptide containing an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85% or at least 90% identity with an amino acid sequence selected from SEQ ID NO: 15 to SEQ ID NO: 62. A peptide containing an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85% or at least 90% identity with the amino acid sequence shown in the above SEQ ID NO, when included in the AAV capsid protein, retains the cell tropism of the AAV capsid protein mutant containing the peptide containing the amino acid sequence shown in the above SEQ ID NO.

[0039] For example, the peptide to be contained in the AAV capsid protein mutant may be a peptide comprising an amino acid sequence represented by the following formula:

[0040] Formula I: X 1 X 2 GX 3 GWV;

[0041] Formula II: X 4 X 5 X 6 X 7 GWV;

[0042] Formula III: X 8 X 9 GX 10 X 11 WV;

[0043] Formula IV: X 12 X 13 GX 14 GX 15 V;

[0044] Formula V:X 16 X 17 GX 18 GWX 19 ;or

[0045] Formula VI: X 20 X 21 GX 22 REX 23 ,

[0046] Where X 1 To X 23 Each of is any amino acid residue, G represents glycine, W represents tryptophan, V represents valine, R represents arginine, and E represents glutamic acid. Preferably, in Formula I (X 1 X 2 GX 3 GWV), X 1 is E (glutamate), G (glycine) or T (threonine), and X 2 is R (arginine), T (threonine), S (serine), N (asparagine), E (glutamic acid) or D (aspartic acid), and X 3 is V (valine), H (histidine), R, M (methionine) or L (leucine). Preferably, in Formula II (X 4 X 5 X 6 X 7 GWV), X 4 A (alanine) or E, X 5D, G or A, X 6 is K (lysine), Q (glutamine) or N, and X 7 is V or L. Preferably, in Formula III (X 8 X 9 GX 10 X 11 WV), X 8 A, E or G, X 9 S, D, G or R, X 10 is T, M, D, or V, and X 11 is R, V, S or T. Preferably, in Formula IV (X 12 X 13 GX 14 GX 15 V), X 12 D, E, G or R, X 13 A, G, D or V, X 14 is I, H, D, F (phenylalanine), G or L, and X 15 is Y (tyrosine), F, R, G or V. Preferably, in formula V (X 16 X 17 GX 18 GWX 19 ), X 16 A, E or G, X 17 G, R or S, X 18 is V, H or D, and X 19 is T, G, K, I (isoleucine) or A. Preferably, in Formula VI (X 20 X 21 GX 22 REX 23 ), X 20 E or A, X 21 Y or H, X 22 is F or Y, and X 23 It is G or P (proline).

[0047] Examples of peptides containing the amino acid sequence shown in Formula I include, but are not limited to, peptides containing an amino acid sequence selected from SEQ ID NOs: 18, 20, 21, 22, 46, 55, 59 and 60, and peptides containing an amino acid sequence different from the amino acid sequence selected from SEQ ID NOs: 18, 20, 21, 22, 46, 55, 59 and 60 due to substitution, deletion, insertion and / or addition of 1 to 3 amino acids. Examples of peptides containing the amino acid sequence shown in Formula II include, but are not limited to, peptides containing an amino acid sequence selected from SEQ ID NOs: 25, 29 and 32, and peptides containing an amino acid sequence different from the amino acid sequence selected from SEQ ID NOs: 25, 29 and 32 due to substitution, deletion, insertion and / or addition of 1 to 4 amino acids. Examples of peptides containing the amino acid sequence represented by Formula III include, but are not limited to, peptides containing an amino acid sequence selected from SEQ ID NOs: 15, 24, 38, 48 and 54, and peptides containing an amino acid sequence different from the amino acid sequence selected from SEQ ID NOs: 15, 24, 38, 48 and 54 due to substitution, deletion, insertion and / or addition of 1 to 4 amino acids. Examples of peptides containing the amino acid sequence represented by Formula IV include, but are not limited to, peptides containing an amino acid sequence selected from SEQ ID NOs: 19, 31, 35, 44, 56 and 58, and peptides containing an amino acid sequence different from the amino acid sequence selected from SEQ ID NOs: 19, 31, 35, 44, 56 and 58 due to substitution, deletion, insertion and / or addition of 1 to 4 amino acids. Examples of peptides containing the amino acid sequence shown by Formula V include, but are not limited to, peptides containing an amino acid sequence selected from SEQ ID NOs: 26, 39, 42, 43, 47 and 50, and peptides containing an amino acid sequence different from the amino acid sequence selected from SEQ ID NOs: 26, 39, 42, 43, 47 and 50 due to substitution, deletion, insertion and / or addition of 1 to 4 amino acids. Examples of peptides containing the amino acid sequence shown by Formula VI include, but are not limited to, peptides containing an amino acid sequence shown by SEQ ID NOs: 16 or 17, and peptides containing an amino acid sequence different from the amino acid sequence shown by SEQ ID NOs: 16 or 17 due to substitution, deletion, insertion and / or addition of 1 to 4 amino acids.

[0048] The AAV capsid protein mutant encoded by the nucleic acid of the present invention can be prepared by inserting the peptide into the AAV capsid protein of any wild-type AAV (e.g., AAV type 1 (AAV1), AAV type 2 (AAV2), AAV type 3 (AAV3A, AAV3B, etc.), AAV type 4 (AAV4), AAV type 5 (AAV5), AAV type 6 (AAV6), AAV type 7 (AAV7), AAV type 8 (AAV8), AAV type 9 (AAV9), AAV type 10 (AAV10), AAV type 11 (AAV11), bird AAV, bovine AAV, dog AAV, horse AAV, or sheep AAV), or replacing part of the amino acid sequence of the AAV capsid protein with the peptide (in other words, by making the AAV capsid protein contain the peptide). In the present invention, the capsid protein of AAV2 is preferably used.

[0049] The AAV capsid protein mutant encoded by the nucleic acid of the present invention may be a protein containing one or more or several amino acid substitutions, deletions, insertions and / or additions and the above-mentioned peptides in the wild-type AAV capsid protein. The "protein containing one or more or several amino acid substitutions, deletions, insertions and / or additions and the above-mentioned peptides" retains the characteristics of the original protein, such as the cell tropism, capsid formation ability, and capsid protein functions (such as protection of the viral genome, uncoating after entering the host cell) of the AAV capsid protein mutant conferred by the above-mentioned peptides.

[0050] Further, the spacer sequence can be added to the N-terminus and / or C-terminus of the peptide contained in the AAV capsid protein. The spacer sequence is preferably composed of 1 to 5 amino acid residues. The amino acid residues constituting the spacer sequence are particularly limited. For example, the spacer sequence may include an amino acid selected from glycine, alanine and serine.

[0051] AAV VP1, VP2 or VP3 can be used as the AAV capsid protein containing a peptide. Only any one of VP1, VP2 and VP3 can contain a peptide, or VP1, VP2 and VP3 can all contain a peptide. In addition, two capsid proteins (such as VP1 and VP2, VP2 and VP3 or VP1 and VP3) can contain a peptide. VP1 to VP3 are encoded by the cap gene region in the AAV genome. In one embodiment of the present invention, the region common to VP1 to VP3 is made to contain a peptide, so that mutations can be introduced into the three of VP1 to VP3. In another embodiment of the present invention, a gene encoding VP1, VP2 or VP3 is prepared separately from the cap gene region of AAV, and mutations are introduced into the gene. In this case, the following treatment can be implemented, which inhibits the expression of a wild-type capsid protein corresponding to the capsid protein encoded by the gene into which the mutation has been introduced from the cap gene region of AAV.

[0052] In the case of using AAV2 VP1, the AAV capsid protein mutant encoded by the nucleic acid of the present invention preferably contains a peptide at a position between amino acid number 588 and amino acid number 589. Amino acid number 588 of AAV2 VP1 is arginine. Amino acid number 589 of AAV2VP1 is glutamine. Amino acid number 588 of AAV2 VP1 corresponds to amino acid number 451 of AAV2 VP2 and amino acid number 386 of AAV2 VP3. In the case of using a capsid protein of an AAV serotype and clade other than AAV2 as an AAV capsid protein, the AAV capsid protein contains a peptide between the amino acids corresponding to amino acid numbers 588 and 589 of AAV2 VP1. Those skilled in the art can easily determine the amino acid of the capsid protein of an AAV serotype and clade other than AAV2 corresponding to the amino acid at amino acid number 588 of AAV2 VP1. See, for example, the alignment of VP1 amino acid sequences shown in Gao et al., Proc. Natl. Acad. Sci. USA, Vol. 99, No. 18, pp. 11854-11859, 2002. For example, amino acid number 588 of AAV2 VP1 corresponds to amino acid number 589 of AAV1, amino acid number 590 of AAV7, and amino acid number 591 of AAV8.

[0053] The nucleic acid of the present invention can be operably linked to a suitable control sequence. Examples of control sequences include promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, replication origins, internal ribosome entry sites (IRES), and enhancers. Examples of promoter sequences include inducible promoter sequences and constitutive promoter sequences. The control sequence can be an endogenous or exogenous sequence of AAV (the capsid protein is derived from the AAV), a natural sequence, or a synthetic sequence. The present invention also includes such recombinant DNAs that can express AAV capsid protein mutants.

[0054] The recombinant DNA of the present invention is useful for delivering the nucleic acid of the present invention to cells in vitro, ex vivo or in vivo and conferring the ability to express AAV capsid protein mutants to the cells. The cells to which the nucleic acid of the present invention is delivered are then useful for producing AAV particles. The recombinant DNA is particularly useful for delivering or introducing the nucleic acid of the present invention into animal cells, preferably mammalian cells.

[0055] In the present invention, the recombinant DNA of the present invention can be prepared by using DNA as a vector to retain the nucleic acid of the present invention. For example, plasmid DNA, phage DNA, transposon, cosmid DNA, episomal DNA or viral genome can be used.

[0056] (2) Cells containing the nucleic acid of the present invention

[0057] The present invention also provides a host cell, such as an isolated host cell, comprising a nucleic acid of the present invention (specifically, a recombinant DNA as described in (1) above). For example, an isolated cell is a cell line maintained in vitro. As explained below, the host cell of the present invention is useful for the production of the AAV particles of the present invention. When the host cell of the present invention is used to produce AAV particles, the host cell may be referred to as a "packaging cell" or a "production cell". The host cell of the present invention may contain the recombinant DNA of the present invention as described in (1) above integrated into the genome, or the recombinant DNA may be retained in the cell to transiently express an AAV capsid protein mutant.

[0058] The recombinant DNA of the present invention can be introduced into the host cell by known methods. For example, electroporation, calcium phosphate precipitation, microinjection directly into the cell, liposome-mediated gene transfection or nucleic acid delivery using a high-speed particle gun can be used. When a viral vector is used, an infection method suitable for the vector can be selected. By using such established techniques, the recombinant DNA of the present invention is stably introduced into the chromosome of the host cell or transiently introduced into the cytoplasm of the host cell. For stable transformation, a selection marker, such as a well-known selection marker such as a neomycin resistance gene (encoding neomycin phosphotransferase) or a hygromycin B resistance gene (encoding aminoglycoside phosphotransferase (APH)), can be connected to the recombinant DNA of the present invention.

[0059] Various cells, such as mammalian cells including mouse cells and primate cells (e.g., human cells) or insect cells, can be used as host cells. Examples of suitable mammalian cells include, but are not limited to, primary cells and cell lines. Examples of suitable cell lines include 293 cells, COS cells, HeLa cells, Vero cells, 3T3 mouse fibroblasts, C3H10T1 / 2 fibroblasts, CHO cells, and cells derived therefrom.

[0060] (3) AAV particles comprising an AAV capsid protein containing an amino acid sequence encoded by the nucleic acid of the present invention

[0061] The AAV particles of the present invention are AAV particles containing AAV capsid protein mutants containing the peptides described in (1) above. The AAV particles of the present invention can be produced from host cells as described in (2) above. The AAV particles of the present invention have tropism for the brain and are useful for introducing genes into the brain. The brain includes brain cells such as neuronal cells and glial cells (microglia, oligodendrocytes, astrocytes). The genes introduced by the AAV particles of the present invention are strongly expressed in the above-mentioned tissues, organs and cells.

[0062] In order to produce AAV particles, cells containing some elements necessary for producing AAV particles can be used as packaging cells. The first element is the vector genome (also referred to as expression vector) of recombinant AAV, which can be replicated in host cells and packaged in AAV particles. The recombinant AAV vector genome comprises the heterologous polynucleotide of interest and the AAV reverse terminal repeat (ITR) sequence located on each side (i.e., 5'- and 3'-side) of the heterologous polynucleotide of interest. The heterologous polynucleotide of interest may have a control sequence for expression. The nucleotide sequence of the ITR sequence is known. For example, regarding the AAV2-ITR sequence, see Human Gene Therapy, Vol.5, pp. 793-801, 1994. Any ITR sequence derived from various AAV serotypes (including AAV1, AAV2, AAV3, AAV4, AAV5, AAV7, etc.) can be used as the AAV ITR sequence. The ITR sequence used in the present invention can be derived from wild-type AAV, or can be changed by insertion, deletion or replacement of nucleotides. The ITR sequence enables the recombinant AAV vector genome to replicate in the presence of the Rep protein and enables the recombinant AAV vector genome to be incorporated into the capsid particle during the formation of AAV particles.

[0063] The size of the heterologous polynucleotide of interest that can be loaded into the AAV particles of the present invention is generally less than about 5 kilobases (kb). For example, the heterologous polynucleotide of interest can be a gene encoding a protein of interest that is lacking or deleted in a receptor, a gene encoding a protein with a desired biological or therapeutic activity (e.g., antimicrobial, antiviral, or antitumor activity), a desired nucleotide sequence encoding RNA that inhibits or reduces the production of harmful or undesirable proteins, or a nucleotide sequence encoding an antigenic protein. The heterologous polynucleotide of interest can be appropriately selected according to the purpose.

[0064] In one embodiment of the present invention, the recombinant AAV vector genome lacks the cap gene region and / or the rep gene region. In this embodiment, the AAV particles (in which the recombinant AAV vector genome is packaged) do not replicate alone in infected cells to form AAV particles again.

[0065] The second element necessary for producing AAV particles is a construct that provides a protein encoded in wild-type AAV. The construct encodes an AAV-derived gene that provides the AAV gene product required for AAV particle formation. In other words, the construct contains one or both of the main AAV ORFs (coding regions of the rep gene region and the cap gene region). In order to produce the AAV particles of the present invention, at least a nucleic acid encoding an AAV capsid protein mutant is used as a cap gene, and the mutant contains a peptide having an amino acid sequence selected from SEQ ID NO: 15 to SEQ ID NO: 62. The host cell of the present invention capable of expressing a mutant as described in (2) above can be used for the production of AAV particles. AAV particles have an outer shell composed of many capsid proteins. All capsid proteins may be mutants, or some capsid proteins may be mutants and others may be wild-type capsid proteins. The AAV particles of the present invention may contain one capsid protein mutant or multiple capsid protein mutants.

[0066] The rep gene of AAV is contained in the coding region of the rep gene, and it includes genes encoding replication proteins Rep78, Rep68, Rep52 and Rep40. These Rep expression products have been shown to have many functions, including recognition, binding and nicking of the AAV genomic DNA replication origin, DNA helicase activity, and regulation of transcription of AAV-derived promoters.

[0067] The third element necessary for producing AAV particles is the helper virus function (also referred to as accessory function) of AAV replication. Adenovirus is usually used to introduce helper function. However, other viruses, such as herpes simplex virus type 1 or type 2 and vaccinia virus, may also be used. When using viruses, host cells are infected by viruses that are helper viruses. For example, since the packaging of AAV particles only requires the expression of adenoviral early genes, adenoviruses that do not present late gene expression may also be used. Adenovirus mutants lacking late gene expression (e.g., ts100K or ts149 adenovirus variants) may also be used. A nucleic acid construct providing helper virus function may also be prepared by using nucleic acids separated from helper viruses necessary for helper virus function, which may then be introduced into host cells. The construct providing helper virus function comprises a nucleotide sequence that provides one or more helper virus functions, and it is provided to the host cell in the form of a plasmid, phage, transposon, clay or other virus.

[0068] In order to produce AAV particles, (a) the step of introducing the first element, i.e., the recombinant AAV vector genome, into the host cell, (b) the step of introducing the second element, i.e., the construct providing the AAV auxiliary function, into the host cell, and (c) the step of introducing the third element, i.e., the helper virus function, into the host cell are implemented. These steps can be implemented simultaneously, or can be implemented sequentially. The order of steps (a) to (c) can be in any order. When the first to third elements are introduced into the host cell, the rep gene expression product cuts off and replicates the recombinant vector genome. The expressed capsid protein forms a capsid, and the recombinant vector genome is packaged in the capsid to produce AAV particles. When the host cell expresses an AAV capsid protein mutant, the shell of the AAV particles produced contains the AAV capsid protein mutant.

[0069] AAV particles can be separated and purified from the culture supernatant or lysate of host cells by various purification methods (such as CaCl density gradient centrifugation). For example, when a virus is used in the above step (c), a step of separating AAV particles from helper viruses based on their size can be added. AAV particles can also be separated from helper viruses based on different affinities for heparin. In addition, the remaining helper viruses can be inactivated by known methods. For example, adenovirus can be inactivated by heating at about 60°C, for example, for 20 minutes or more. Since AAV particles are very stable to heat, the above treatment is effective for selectively removing adenovirus used as helper virus.

[0070] (4) Method for producing gene-transduced cells of the present invention

[0071] For gene therapy purposes or other purposes, the AAV particles of the present invention obtained by (3) above are used to deliver the heterologous polynucleotide of interest to cells. AAV particles are generally introduced into cells in vivo or in vitro. For in vitro introduction, AAV particles are contacted with cells obtained from a living body. Then, the cells can also be transplanted into a living body. For introducing cells into a living body, the cells are formulated as a pharmaceutical composition, and various techniques such as intramuscular, intravenous, subcutaneous and intraperitoneal administration can be used. For in vivo transduction, AAV particles are formulated as a pharmaceutical composition, and they are generally administered parenterally (e.g., by intramuscular, subcutaneous, intratumoral, transdermal or intraspinal routes). Pharmaceutical compositions comprising AAV particles may contain a pharmaceutically acceptable carrier, and, if necessary, other agents, drugs, stabilizers, carriers, adjuvants, diluents, etc. Example

[0072] Hereinafter, the present invention is described with reference to Examples, but the present invention is not particularly limited to the Examples.

[0073] Example 1: Preparation of AAV2 random peptide plasmid library

[0074] From the distribution host Escherichia coli ( Escherichia coli )HB101 was used to extract the plasmid vector pAV1 (ATCC No.: 37215) carrying the AAV2 genome. The AAV2 genomic DNA (about 4.7 kb) was cut out from the extracted plasmid using the restriction enzyme BgIII (produced by TAKARA BIO Inc.). The genomic DNA was inserted into pUC118 BamHI / BAP (produced by TAKARA BIO Inc.). The plasmid DNA thus obtained was named AAV2WG / pUC118.

[0075] AAV2WG / pUC118 was digested with restriction enzyme ScaI (manufactured by TAKARA BIO Inc.) to obtain a fragment of about 0.8 kb containing nucleotides 1190 to 2017 of the cap gene. This fragment was inserted into pUC118 HincII / BAP (manufactured by TAKARA BIO Inc.). The plasmid DNA thus obtained was named Cap-ScaI / pUC118. Then, Cap-ScaI / pUC118 was subjected to PCR to perform a series of changes in which the nucleotide sequence AAC (587N) consisting of nucleotides 1759 to 1761 of the Cap gene in Cap-ScaI / pUC118 was converted to CAG (587Q), 10 nucleotides consisting of GGC as a spacer, CAAG as a filler, and GCC as a spacer were inserted between nucleotides 1764 and 1765, and the nucleotide sequence CAA (589Q) GCA (590A) GCT (591A) consisting of nucleotides 1765 to 1773 was converted to CAG (589Q) GCG (590A) GCC (591A), wherein the text in brackets shows the amino acid number and the encoded amino acid. Thus, two recognition sites for the restriction enzyme SfiI and a spacer, filler, and spacer between the SfiI recognition sites were inserted. Figure 1 The nucleotide sequences before and after the conversion of nucleotides 1756 to 1773 of the Cap gene are shown. The nucleotide sequence before the conversion is shown in SEQ ID NO: 1 of the sequence listing. The nucleotide sequence after the conversion is shown in SEQ ID NO: 2. The plasmid DNA containing the converted nucleotide sequence was named Cap-ScaI-S4 / pUC118. For in-fusion cloning, the Cap gene portion in Cap-ScaI-S4 / pUC118 was amplified by PCR to obtain a fragment of about 0.8 kb. This fragment was used as the insert DNA.

[0076] AAV2WG / pUC118 was subjected to PCR to introduce mutations into the recognition site of the restriction enzyme ScaI in the ampicillin resistance gene and the recognition site of the restriction enzyme SfiI in the Rep gene, so that these recognition sites were converted into sequences that are not recognized by the restriction enzymes. For the ScaI recognition site, the nucleotide sequence GAG(E) consisting of nucleotides 304 to 306 of the ampicillin resistance gene was converted to GAA(E). The sequence before conversion is shown in SEQ ID NO: 3, and the sequence after conversion is shown in SEQ ID NO: 4. For the SfiI recognition site, the nucleotide sequence GCC(A) consisting of nucleotides 217 to 219 of the Rep gene was converted to GCA(A). The sequence before conversion is shown in SEQ ID NO: 5, and the sequence after conversion is shown in SEQ ID NO: 6. The plasmid DNA thus obtained was digested with ScaI (manufactured by TAKARA BIO Inc.) to obtain a linear vector of about 0.8 kb lacking a part of the Cap gene. This was used as a linear vector for in-fusion cloning.

[0077] Using In-Fusion (registered trademark) HD ​​Cloning Kit (manufactured by Clontech Laboratories, Inc.) and Cloning Enhancer (manufactured by Clontech Laboratories, Inc.), the insert DNA was inserted into the linear vector, and directional cloning was thereby performed. The plasmid DNA thus obtained was named AAV2WG-Cap-ScaI-S4 / pUC118Sx.

[0078] An oligo DNA (SEQ ID NO: 7) containing a nucleotide sequence encoding a random peptide of 7 amino acids was produced by artificial synthesis. Double-stranded DNA was prepared from the oligo DNA by reacting with a primer (SEQ ID NO: 8) and a Klenow fragment (produced by TAKARA BIO Inc.) at 37°C for 3 hours. The double-stranded DNA was purified using a Nucleotide removal kit (produced by QIAGEN) and then digested with a restriction enzyme BglI (produced by TAKARA BIO Inc.). This DNA was inserted into AAV2WG-Cap-ScaI-S4 / pUC118Sx digested with SfiI using a DNA ligation kit "Mighty Mix" (produced by TAKARA BIO Inc.). The plasmid thus obtained was named AAV2WG-RPL / pUC118Sx and used as an AAV2 random peptide plasmid library.

[0079] Example 2: Preparation of AAV2 random peptide virus library

[0080] (1) Inoculation of AAV293 cells

[0081] The cultured AAV293 cells (manufactured by Stratagene Corp.) were collected and then incubated at 5×10 cells / mL in DMEM (manufactured by Sigma) containing 10% FBS and 2 mM sodium L-glutamate. 4 Place 40 mL of the suspension containing AAV293 cells into a T225 cm 2 The cells were placed in flasks (manufactured by Corning Incorporated), which were then cultured in a CO2 incubator at 37°C for 72 hours.

[0082] (2) Introducing plasmid into AAV293 cells

[0083] AAV293 cells were transfected with 400 ng of AAV2WG-RPL / pUC118Sx obtained in Example 1 and 40 μg of pHELP (produced by CELL BIOLABS, Inc.) by a general calcium phosphate method. Six hours after transfection, the medium was completely removed. After adding 40 mL of DMEM containing 2% FBS and 2 mM sodium L-glutamate, the cells were cultured in a CO2 incubator at 37°C for 48 hours.

[0084] (3) Collecting AAV2 random peptide virus library

[0085] Add 0.5 mL of 0.5 M EDTA to the incubating T225 cm 2 bottle, and then let it stand for a few minutes. The AAV293 cells were then stripped by pipetting and collected in a 50 mL tube, and centrifuged at 300 xg for 10 minutes. The supernatant was then removed. The cells were resuspended in 2 mL TBS (Tris buffered saline) per bottle, and then treated three times in a row to collect cell lysates containing the AAV random peptide virus library, the continuous treatment consisting of freezing with ethanol / dry ice for 15 minutes, thawing in a 37°C water bath for 15 minutes, and vortexing for 1 minute. 5 μL 1 MMgCl2 was added to the cell lysate per 1 mL TBS, and Benzonase (registered trademark) nuclease (produced by Merck KGaA) was added at a final concentration of 200 U / mL, and then reacted at 37°C for 30 minutes. The reaction was then terminated by adding 6.5 μL 0.5 M EDTA per 1 mL TBS. The cell lysate was centrifuged at 10,000 rpm at 4°C for 10 minutes, and the supernatant was collected as an AAV vector solution.

[0086] (4) Quantification of AAV vector solution titer by real-time PCR

[0087] 2 μL 10 X DNaseI buffer, 15.2 μL water for injection (produced by Otsuka Pharmaceutical Co., Ltd.) and 0.8 μL DNaseI (produced by TAKARA BIO Inc.) were added to 2 μL AAV vector solution, and the mixture was incubated at 37°C for 1 hour to remove free genomic DNA and plasmid DNA. To inactivate DNaseI, the mixture was heated at 99°C for 10 minutes. Then 15 μL water for injection, 4 μL 10 X ProK buffer (0.1 M Tris-HCl (pH7.8), 0.1 M EDTA, 5% SDS) and 1 μL proteinase K (produced by TAKARA BIO Inc.) were added, and the mixture was incubated at 55°C for 1 hour. Then, to inactivate proteinase K, the mixture was heated at 95°C for 10 minutes. AAV titer quantification was performed on this sample using SYBR (registered trademark) Premix ExTaq2 (manufactured by TAKARA BIO Inc.) and primers (SEQ ID NO: 9 and SEQ ID NO: 10) according to the instructions attached to the kit. The sample was diluted 50 times with water for injection, and 2 μL of the diluted solution was used for titer quantification. Linear DNA obtained by digesting pAV1 with restriction enzymes was used as a standard.

[0088] Example 3: Purification of AAV random peptide virus library

[0089] (1) Purification by cesium chloride density gradient centrifugation 1

[0090] In a 40PA tube for ultracentrifugation (manufactured by HITACHI-KOKI Co., Ltd.), 4 mL of a cesium chloride solution whose density was adjusted to 1.5, 4 mL of a cesium chloride solution whose density was adjusted to 1.25, and 28 mL of the AAV vector solution prepared in Example 2-(4) were layered in this order from the bottom. The tube was centrifuged at 25,000 rpm at 16°C for 3 hours using an ultracentrifuge HIMAC (manufactured by HITACHI-KOKI Co., Ltd.). After centrifugation, 28 mL of the solution was removed from the upper part of the tube, and then aliquots of 0.7 mL of the solution were successively collected from the upper part into 1.5 mL tubes. In the same manner as in Example 2-(4), the titer of the AAV vector contained in each collected solution was quantified.

[0091] (2) Purification by cesium chloride density gradient centrifugation

[0092] In several parts showing high titers in Example 3-(1), a cesium chloride solution whose density was adjusted to 1.39 was added to reach a total volume of 10.5 mL. The solution thus obtained was placed in a 13PA tube for ultracentrifugation (manufactured by HITACHI-KOKI Co., Ltd.), and then centrifuged at 38,000 rpm at 18°C ​​for 16 hours. After centrifugation, aliquots of 0.7 mL of the solution were collected from the upper part of the tube one after another. The titer of the AAV vector contained in each collected solution was quantified in the same manner as in Example 2-(4).

[0093] (3) Desalination by dialysis

[0094] The multiple fractions showing high titers in Example 3-(2) were mixed and then added to a Slide-A-lyzer dialysis card (manufactured by Pierce). The purified AAV solution was desalted by dialysis with 1 L of phosphate buffered saline (PBS) at 4°C for 3 hours twice and with 500 mL of PBS / 5% sorbitol solution at 4°C overnight. The solution was then collected, sterilized with a 0.22 μm filter (manufactured by Millipore) and stored at -80°C until immediately before use. The titers of the purified AAV particles were quantified in the same manner as in Example 2-(4).

[0095] Example 4: AAV2 random peptide library screening

[0096] (1) Mouse tail vein administration

[0097] The purified AAV particles obtained in Example 3-(3) were diluted to 1.5 x 10 14 Viral genome (VG) / kg was administered to BALB / c mice via the tail vein. 72 hours after administration, the brain was collected and genomic DNA was extracted by using NucleoSpin (registered trademark) tissue (manufactured by MACHEREY-NAGEL GmbH & Co. KG) (Round 1).

[0098] (2) Recloning of random peptide sequences using PCR

[0099] The genomic DNA extracted in Example 4-(1) was used as a template and PrimeSTAR (registered trademark) GXLDNA polymerase (produced by TAKARA BIO Inc.) was used to amplify DNA encoding a random peptide sequence. Forward primer 1 (SEQ ID NO: 11) and reverse primer 1 (SEQ ID NO: 12) were used as primers. PCR was performed by repeating 30 cycles, and each cycle of PCR consisted of 98°C 10 seconds, 55°C 15 seconds and 68°C 40 seconds. Then, a reaction mixture of the same amount as the previous amount was prepared using one-twentieth of the PCR reaction solution, forward primer 2 (SEQ ID NO: 13) and reverse primer 2 (SEQ ID NO: 14). The reaction mixture was subjected to 30 cycles of PCR, each cycle consisting of 98°C 10 seconds, 55°C 15 seconds and 68°C 15 seconds. DNA was purified from the reaction solution thus obtained by using Nucleospin extract II (produced by MACHEREY-NAGEL GmbH & Co. KG), and digested with restriction enzyme BglI. After electrophoresis, the digestion product was purified by using Nucleospinextract II, and recloned into AAV2WG-Cap-ScaI-S4 / pUC118Sx prepared in Example 1 by using a DNA ligation kit "Mighty Mix".

[0100] (3) Generation and purification of AAV2 random peptide viral library

[0101] AAV2 random peptide virus library production and purification of AAV particles were performed in the same manner as those described in Examples 2 and 3 using the plasmid obtained in Example 4-(2).

[0102] (4) Screening

[0103] Screening was performed in the same manner as in Example 4-(1) (administration of AAV particles to mice and collection of brains) and genomic DNA was extracted (Round 2). In addition, using the extracted genomic DNA, re-cloning, library generation and purification, and screening were performed again, and genomic DNA was extracted (Round 3).

[0104] (5) Random Peptide Sequencing

[0105] At each screening stage (round 1 to round 3), the AAV random peptide plasmid library was sequenced. The peptide sequences encoded by clones accumulated in the brain in rounds 2 and 3 and the frequencies of occurrence are shown in Tables 1 and 2.

[0106] [Table 1]

[0107]

[0108] [Table 2]

[0109]

[0110] As shown in Tables 1 and 2, AAVs having capsids containing specific peptide sequences accumulated in the brain. In particular, it was suggested that the peptide sequences GSGVTWV (SEQ ID NO: 15), AHGYREP (SEQ ID NO: 16), EYGFREG (SEQ ID NO: 17), and ETGHGWV (SEQ ID NO: 18) observed in round 3 tend to infect the brain.

[0111] In addition, it was suggested that the peptide sequences of SEQ ID NO: 63 to SEQ ID NO: 110 tend to infect the brain, which are sequences including the sequence and the spacer observed in round 2. In particular, GGSGVTWVA (SEQ ID NO: 63), GAHGYREPA (SEQ ID NO: 64), GEYGFREGA (SEQ ID NO: 65), and GETGHGWVA (SEQ ID NO: 66), which are sequences including the sequence and the spacer observed in round 3, tend to infect the brain.

[0112] Example 5: Evaluation of the tropism of AAV vectors with acquired peptide sequences

[0113] (1) Construction of pRC-GDDGTRG with the obtained peptide sequence

[0114] AAV2WG-Cap-ScaI-S4 / pUC118Sx clones having the peptide sequences (SEQ ID NOs: 15-20) obtained in Example 4-(5) were digested with restriction enzymes SnaBI (manufactured by TAKARA BIO Inc.) and HindIII (manufactured by TAKARA BIO Inc.) to obtain fragments. The fragments were ligated to a vector fragment obtained by digesting a pAAVRC2 vector (manufactured by CELL BIOLABS, Inc.) with SnaBI and HindIII using a DNA ligation kit (manufactured by TAKARA BIO Inc.) to obtain helper plasmids pRC-GSGVTWV, pRC-AHGYREP, pRC-EYGFREG, pRC-ETGHGWV, pRC-GGGIGYV, and pRC-ERGVGWV.

[0115] (2) Production and purification of AAV2-LacZ capsid mutants

[0116] pAAV-LacZ (manufactured by TAKARA BIO Inc.), pHELP, and the pRC helper plasmid prepared in Example 5-(1) (pRC-GSGVTWV, pRC-AHGYREP, pRC-EYGFREG, pRC-ETGHGWV, pRC-GGGIGYV, or pRC-ERGVGWV) were used to inoculate cells at T255 cm 2 The 293 T cells in the flask were transfected with PEIpro (manufactured by Polyplus Transfection). As a control, transfection with a pRC2 vector carrying a wild-type capsid instead of the pRC helper plasmid with the peptide sequence was performed. The transfected 293 T cells were cultured at 37°C in a CO2 incubator for 72 hours. 2 The supernatant containing AAV was collected in the bottle and then affinity purified using AVB agarose gel (manufactured by GE healthcare). Then, AAV was concentrated and purified by ultrafiltration to prepare a purified AAV solution. Then, the titer of the AAV vector was quantified by the method described in Example 2-(4).

[0117] (3) Administration of purified AAV solution to mice

[0118] The purified AAV solution obtained in Example 5-(2) was filtered using a 0.22 μm filter and then injected into the culture medium via the tail vein at a concentration of 0.5 × 10 11 VG / mouse was administered to mice.

[0119] (4) Preparation of genomic DNA from brain and other tissues and quantification of AAV genomes

[0120] The mice (to which AAV was administered in Example 5-(3)) were euthanized 4 weeks after administration, and each tissue was collected. Genomic DNA was extracted from each tissue by using NucleoSpin tissue (manufactured by MACHEREY-NAGEL GmbH & Co. KG). The extracted genomic DNA was used as a sample and subjected to real-time PCR to determine the amount of AAV vector genome contained in each tissue. Figure 2 The number of AAV genomic DNA molecules per 1 μg of total genomic DNA in each tissue is shown.

[0121] like Figure 2 As can be seen in , AAV vectors containing capsids having the peptide sequences GSGVTWV, AHGYREP, EYGFREG, ETGHGWV, GGGIGYV, and ERGVGWV tend to transfer to the brain. Further, some AAV vectors have tropism for the lung as well as the brain.

[0122] Industrial Applicability

[0123] According to the present invention, AAV capsid protein mutants having brain tropism upon systemic administration and their amino acid sequences are provided, and thereby a method for efficiently introducing genes into the brain is provided.

[0124] Sequence Listing Free Text

[0125] SEQ ID NO: 1: AAV2 capsid 586-591 coding sequence

[0126] SEQ ID NO: 2: Switched AAV2 capsid coding sequence

[0127] SEQ ID NO: 3: Ampicillin resistance gene before conversion

[0128] SEQ ID NO: 4: Ampicillin resistance gene after conversion

[0129] SEQ ID NO: 5: AAV2 rep gene before conversion

[0130] SEQ ID NO: 6: AAV2 rep gene after conversion

[0131] SEQ ID NO: 7: DNA sequence encoding random peptide

[0132] SEQ ID NO: 8: Primer for synthesizing double-stranded DNA

[0133] SEQ ID NO: 9: Forward primer for quantification of AAV titer

[0134] SEQ ID NO: 10: Reverse primer for quantification of AAV titer

[0135] SEQ ID NO: 11: Forward primer 1 for random peptide coding region amplification

[0136] SEQ ID NO: 12: Reverse primer 1 for random peptide coding region amplification

[0137] SEQ ID NO: 13: Forward primer 2 for random peptide coding region amplification

[0138] SEQ ID NO: 14: Reverse primer 2 for random peptide coding region amplification

[0139] SEQ ID NO: 15: Peptide sequence of AAV capsid protein mutant GSGVTWV

[0140] SEQ ID NO: 16: Peptide sequence of AAV capsid protein mutant AHGYREP

[0141] SEQ ID NO: 17: Peptide sequence EYGFREG of AAV capsid protein mutant

[0142] SEQ ID NO: 18: Peptide sequence of AAV capsid protein mutant ETGHGWV

[0143] SEQ ID NO: 19: Peptide sequence of AAV capsid protein mutant GGGIGYV

[0144] SEQ ID NO: 20: Peptide sequence ERGVGWV of AAV capsid protein mutant

[0145] SEQ ID NO: 21: Peptide sequence of AAV capsid protein mutant ENGVGWV

[0146] SEQ ID NO: 22: Peptide sequence of AAV capsid protein mutant GSGVGWV

[0147] SEQ ID NO: 23: Peptide sequence of AAV capsid protein mutant ADGITWG

[0148] SEQ ID NO: 24: Peptide sequence of AAV capsid protein mutant ADGTRWV

[0149] SEQ ID NO: 25: Peptide sequence of AAV capsid protein mutant ADKVGWV

[0150] SEQ ID NO: 26: Peptide sequence of AAV capsid protein mutant AGGVGWT

[0151] SEQ ID NO: 27: Peptide sequence of AAV capsid protein mutant AGGVTGV

[0152] SEQ ID NO: 28: Peptide sequence AGNAGGM of AAV capsid protein mutant

[0153] SEQ ID NO: 29: Peptide sequence of AAV capsid protein mutant AGQLGWV

[0154] SEQ ID NO: 30: Peptide sequence of AAV capsid protein mutant ARGTEWE

[0155] SEQ ID NO: 31: Peptide sequence of AAV capsid protein mutant DAGHGFV

[0156] SEQ ID NO: 32: Peptide sequence of AAV capsid protein mutant EANVGWV

[0157] SEQ ID NO: 33: Peptide sequence of AAV capsid protein mutant ECGLGEG

[0158] SEQ ID NO: 34: Peptide sequence of AAV capsid protein mutant EGEVTWL

[0159] SEQ ID NO: 35: Peptide sequence of AAV capsid protein mutant EGGDGRV

[0160] SEQ ID NO: 36: Peptide sequence of AAV capsid protein mutant EGGFGEA

[0161] SEQ ID NO: 37: Peptide sequence EGGG of AAV capsid protein mutant

[0162] SEQ ID NO: 38: Peptide sequence of AAV capsid protein mutant EGGMVWV

[0163] SEQ ID NO: 39: Peptide sequence of AAV capsid protein mutant EGGVGWT

[0164] SEQ ID NO: 40: Peptide sequence of AAV capsid protein mutant EGGVMWL

[0165] SEQ ID NO: 41: Peptide sequence of AAV capsid protein mutant EGQVTWL

[0166] SEQ ID NO: 42: Peptide sequence of AAV capsid protein mutant ERGHGWG

[0167] SEQ ID NO: 43: Peptide sequence ESGVGWK of AAV capsid protein mutant

[0168] SEQ ID NO: 44: Peptide sequence of AAV capsid protein mutant GDGFGGV

[0169] SEQ ID NO: 45: Peptide sequence of AAV capsid protein mutant GDGVTWA

[0170] SEQ ID NO: 46: Peptide sequence of AAV capsid protein mutant GEGRGWV

[0171] SEQ ID NO: 47: Peptide sequence of AAV capsid protein mutant GGGDGWI

[0172] SEQ ID NO: 48: Peptide sequence of AAV capsid protein mutant GGGDSWV

[0173] SEQ ID NO: 49: Peptide sequence of AAV capsid protein mutant GGGIAWVAQAAL

[0174] SEQ ID NO: 50: Peptide sequence of AAV capsid protein mutant GGGVGWA

[0175] SEQ ID NO: 51: Peptide sequence of AAV capsid protein mutant GKGQVME

[0176] SEQ ID NO: 52: Peptide sequence of AAV capsid protein mutant GNGTGGG

[0177] SEQ ID NO: 53: Peptide sequence of AAV capsid protein mutant GQGGHME

[0178] SEQ ID NO: 54: Peptide sequence of AAV capsid protein mutant GRGVTWV

[0179] SEQ ID NO: 55: Peptide sequence of AAV capsid protein mutant GSGMGWV

[0180] SEQ ID NO: 56: Peptide sequence of AAV capsid protein mutant GVGGGVV

[0181] SEQ ID NO: 57: Peptide sequence of AAV capsid protein mutant NDVRGRV

[0182] SEQ ID NO: 58: Peptide sequence of AAV capsid protein mutant RDGLGFV

[0183] SEQ ID NO: 59: Peptide sequence of AAV capsid protein mutant TDGLGWV

[0184] SEQ ID NO: 60: Peptide sequence of AAV capsid protein mutant TEGHGWV

[0185] SEQ ID NO: 61: Peptide sequence of AAV capsid protein mutant VAERLYG

[0186] SEQ ID NO: 62: Peptide sequence of AAV capsid protein mutant VARGAGE

[0187] SEQ ID NO: 63: Peptide sequence of AAV capsid protein mutant GGSGVTWVA

[0188] SEQ ID NO: 64: Peptide sequence of AAV capsid protein mutant GAHGYREPA

[0189] SEQ ID NO: 65: Peptide sequence of AAV capsid protein mutant GEYGFREGA

[0190] SEQ ID NO: 66: Peptide sequence of AAV capsid protein mutant GETGHGWVA

[0191] SEQ ID NO: 67: Peptide sequence of AAV capsid protein mutant GGGGIGYVA

[0192] SEQ ID NO: 68: Peptide sequence of AAV capsid protein mutant GERGVGWVA

[0193] SEQ ID NO: 69: Peptide sequence of AAV capsid protein mutant GENGVGWVA

[0194] SEQ ID NO: 70: Peptide sequence of AAV capsid protein mutant GGSGVGWVA

[0195] SEQ ID NO: 71: Peptide sequence of AAV capsid protein mutant GADGITWGA

[0196] SEQ ID NO: 72: Peptide sequence of AAV capsid protein mutant GADGTRWVA

[0197] SEQ ID NO: 73: Peptide sequence of AAV capsid protein mutant GADKVGWVA

[0198] SEQ ID NO: 74: Peptide sequence of AAV capsid protein mutant GAGGVGWTA

[0199] SEQ ID NO: 75: Peptide sequence of AAV capsid protein mutant GAGGVTGVA

[0200] SEQ ID NO: 76: Peptide sequence of AAV capsid protein mutant GAGNAGGMA

[0201] SEQ ID NO: 77: Peptide sequence of AAV capsid protein mutant GAGQLGWVA

[0202] SEQ ID NO: 78: Peptide sequence of AAV capsid protein mutant GARGTEWEA

[0203] SEQ ID NO: 79: Peptide sequence of AAV capsid protein mutant GDAGHGFVA

[0204] SEQ ID NO: 80: Peptide sequence of AAV capsid protein mutant GEANVGWVA

[0205] SEQ ID NO: 81: Peptide sequence of AAV capsid protein mutant GECGLGEGA

[0206] SEQ ID NO: 82: Peptide sequence of AAV capsid protein mutant GEGEVTWLA

[0207] SEQ ID NO: 83: Peptide sequence of AAV capsid protein mutant GEGGDGRVA

[0208] SEQ ID NO: 84: Peptide sequence of AAV capsid protein mutant GEGGFGEAA

[0209] SEQ ID NO: 85: Peptide sequence GEGGGA of AAV capsid protein mutant

[0210] SEQ ID NO: 86: Peptide sequence of AAV capsid protein mutant GEGGMVWVA

[0211] SEQ ID NO: 87: Peptide sequence of AAV capsid protein mutant GEGGVGWTA

[0212] SEQ ID NO: 88: Peptide sequence of AAV capsid protein mutant GEGGVMWLA

[0213] SEQ ID NO: 89: Peptide sequence of AAV capsid protein mutant GEGQVTWLA

[0214] SEQ ID NO: 90: Peptide sequence of AAV capsid protein mutant GERGHGWGA

[0215] SEQ ID NO: 91: Peptide sequence of AAV capsid protein mutant GESGVGWKA

[0216] SEQ ID NO: 92: Peptide sequence of AAV capsid protein mutant GGDGFGGVA

[0217] SEQ ID NO: 93: Peptide sequence of AAV capsid protein mutant GGDGVTWAA

[0218] SEQ ID NO: 94: Peptide sequence of AAV capsid protein mutant GGEGRGWVA

[0219] SEQ ID NO: 95: Peptide sequence of AAV capsid protein mutant GGGGDGWIA

[0220] SEQ ID NO: 96: Peptide sequence of AAV capsid protein mutant GGGGDSWVA

[0221] SEQ ID NO: 97: Peptide sequence of AAV capsid protein mutant GGGGIAWVAQAALA

[0222] SEQ ID NO: 98: Peptide sequence of AAV capsid protein mutant GGGGVGWAA

[0223] SEQ ID NO: 99: Peptide sequence of AAV capsid protein mutant GGKGQVMEA

[0224] SEQ ID NO: 100: Peptide sequence of AAV capsid protein mutant GGNGTGGGA

[0225] SEQ ID NO: 101: Peptide sequence of AAV capsid protein mutant GGQGGHMEA

[0226] SEQ ID NO: 102: Peptide sequence of AAV capsid protein mutant GGRGVTWVA

[0227] SEQ ID NO: 103: Peptide sequence of AAV capsid protein mutant GGSGMGWVA

[0228] SEQ ID NO: 104: Peptide sequence of AAV capsid protein mutant GGVGGGVVA

[0229] SEQ ID NO: 105: Peptide sequence of AAV capsid protein mutant GNDVRGRVA

[0230] SEQ ID NO: 106: Peptide sequence of AAV capsid protein mutant GRDGLGFVA

[0231] SEQ ID NO: 107: Peptide sequence of AAV capsid protein mutant GTDGLGWVA

[0232] SEQ ID NO: 108: Peptide sequence of AAV capsid protein mutant GTEGHGWVA

[0233] SEQ ID NO: 109: Peptide sequence of AAV capsid protein mutant GVAERLYGA

[0234] SEQ ID NO: 110: Peptide sequence of AAV capsid protein mutant GVARGAGEA

[0235] SEQ ID NO: 111: Peptide sequence represented by Formula I

[0236] SEQ ID NO: 112: Peptide sequence represented by Formula II

[0237] SEQ ID NO: 113: Peptide sequence represented by Formula III

[0238] SEQ ID NO: 114: Peptide sequence represented by Formula IV

[0239] SEQ ID NO: 115: Peptide sequence represented by Formula V

[0240] SEQ ID NO: 116: Peptide sequence represented by Formula VI.

Claims

1. A nucleic acid encoding a mutant of an adeno-associated virus (AAV) capsid protein, into which a peptide consisting of the amino acid sequence of SEQ ID NO: 18 is inserted, or a spacer sequence and a peptide consisting of the amino acid sequence of SEQ ID NO: 18 are inserted, wherein the peptide is placed at a position in the AAV capsid protein between amino acids corresponding to amino acid number 588 and amino acid number 589 of AAV2 VP1.

2. The nucleic acid according to claim 1, wherein the AAV capsid protein is derived from AAV2.

3. A recombinant DNA comprising a nucleic acid according to any one of claims 1 or 2.

4. A cell comprising a nucleic acid according to claim 1 or 2 or a recombinant DNA according to claim 3.

5. An AAV particle comprising a mutant of an AAV capsid protein, into which is inserted a peptide consisting of the amino acid sequence of SEQ ID NO: 18 or a spacer sequence and a peptide consisting of the amino acid sequence of SEQ ID NO: 18, wherein the peptide is placed at a position in the AAV capsid protein between amino acids corresponding to amino acid number 588 and amino acid number 589 of AAV2 VP1.

6. The AAV particle according to claim 5, wherein the AAV capsid protein is derived from AAV2.

7. A method for producing gene-transduced cells, the method comprising the step of contacting an AAV particle comprising a mutant of an AAV capsid protein into which a peptide consisting of the amino acid sequence of SEQ ID NO: 18 is inserted, or a spacer sequence and a peptide consisting of the amino acid sequence of SEQ ID NO: 18 are inserted, with a cell, wherein the peptide is placed at a position in the AAV capsid protein between amino acids corresponding to amino acid number 588 and amino acid number 589 of AAV2 VP1.

8. The method according to claim 7, wherein the AAV capsid protein is derived from AAV2.

Citation Information

Patent Citations

  • AAV variant

    CN104937100A

  • Further improved aav vectors produced in insect cells

    CN106459984A

  • Adeno-associated virus variant capsids and methods of use thereof

    CN109476707A

  • Viral vectors for targeted gene transfer into the brain and spinal cord

    JP2017513486A

  • AAV scleroprotein, production and use thereof

    US20070238684A1